Quantcast

Latest Benzamides Stories

2014-05-30 16:24:41

SAN DIEGO, May 30, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the Jefferies 2014 Global Healthcare Conference. The presentation will take place at 8:00 am EDT on Wednesday, June 4, 2014 at the Grand Hyatt, New York. A live webcast of the presentation can...

2014-05-15 04:22:50

INDIANAPOLIS, May 15, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the English High Court has determined that the vitamin dosage regimen patents for Alimta(®) (pemetrexed) would not be infringed by a generic competitor that has stated an intent to market certain alternative salt forms of pemetrexed in several European countries upon expiry of the Alimta compound patents in 2015. The decision came in the case of Actavis UK Limited and others v. Eli Lilly...

2014-05-09 20:23:02

Supply of paclitaxel will not be disrupted for Canadian patients OTTAWA, May 9, 2014 /CNW/ - Health Canada today confirmed it has suspended the establishment licence of Biolyse Pharma Corporation's facility in St. Catharines, Ont., because of significant concerns with the manufacturing process discovered during a recent inspection. Injectable paclitaxel (6mg/ml), used in the treatment of certain lung and breast cancers, is currently the only drug produced at that facility....

2014-04-15 12:30:07

Potential U.S. Commercialization in 2014 CHICAGO, April 15, 2014 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration (FDA) has granted approval for the name Rasuvo(TM) for the company's lead compound, MPI-2505, a subcutaneous injectable methotrexate (MTX) delivered in a ready-to-use autopen. Currently under...

2014-04-04 12:27:03

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq(TM) and Abraxane(®) (nab-paclitaxel) pharmacokinetics (PK) from animal studies. The PK data will be presented by Dr. Kouros Motamed, Vice President of Clinical Development & Nanomedicine on April 9 from 8:00 AM to...

2014-04-01 00:21:53

SAN DIEGO, March 31, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced that the first patient has been dosed in the pivotal clinical trial designed to support approval of Cynviloq for the treatment of metastatic breast cancer and non-small cell lung cancer. The registration trial referred to as TRIBECA(TM) (TRIal designed to evaluate BioEquivalence...

2014-03-28 12:21:55

DUBLIN, Mar. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/cvsjq3/investigation ) has announced the addition of the "Investigation Report on China Pemetrexed Market, 2009-2018" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market. Approved by FDA...

2014-03-26 08:29:22

Company Seeking Global Marketing Partners for its Proprietary Vitamin B-12 Drug Delivery Technology NEW YORK, March 26, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biotechnology company, announced today that it is leveraging its proprietary CobaCyte(TM) drug delivery platform technology to create new formulations of active pharmaceutical agents. Access recently submitted an additional patent application to protect improvements in the technology and...

2014-03-24 23:24:12

Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Raleigh, NC (PRWEB) March 24, 2014 Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Their findings have just been posted by Surviving Mesothelioma at...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related